These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34854189)

  • 1. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?
    Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
    BJU Int; 2022 Oct; 130(4):463-469. PubMed ID: 34854189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
    Lipsky MJ; Badalato GM; Motamedinia P; Hruby GW; McKiernan JM
    Urology; 2013 Jun; 81(6):1273-8. PubMed ID: 23528913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer.
    Boorjian SA; Berglund RK; Maschino AC; Savage CJ; Herr HW
    J Urol; 2009 Oct; 182(4):1306-12. PubMed ID: 19683284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.
    Contieri R; Grajales V; Tan WS; Martini A; Sood A; Hensley P; Bree K; Lobo N; Nogueras-Gonzalez GM; Guo CC; Navai N; Dinney CP; Kamat AM
    BJU Int; 2024 Jan; 133(1):63-70. PubMed ID: 37442564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
    Lobo N; Bree KK; Hensley PJ; Nogueras-Gonzalez GM; Abraham P; Navai N; Dinney CP; Kamat AM
    BJU Int; 2022 Sep; 130(3):323-330. PubMed ID: 34847263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response.
    Hensley PJ; Bree KK; Brooks N; Matulay J; Li R; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    BJU Int; 2021 Nov; 128(5):634-641. PubMed ID: 33783950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
    Lawler C; Gu L; Howard LE; Branche B; Wiggins E; Srinivasan A; Foster ML; Klaassen Z; De Hoedt AM; Gingrich JR; Theodorescu D; Freedland SJ; Williams SB
    Cancer; 2021 Nov; 127(21):3998-4005. PubMed ID: 34237155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
    Herr HW; Dalbagni G
    BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
    Brooks NA; Kokorovic A; Xiao L; Matulay JT; Li R; Ranasinghe WKB; Nagaraju S; Shen Y; Gao J; Navai N; Dinney CPN; Grossman HB; Kamat AM
    BJU Int; 2021 Jul; 128(1):65-71. PubMed ID: 33210440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
    Gee JR; Jarrard DF; Bruskewitz RC; Moon TD; Hedican SP; Leverson GE; Nakada SY; Messing EM
    BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
    Witjes JA; vd Meijden AP; Doesburg W; Debruyne FM
    Eur Urol; 1993; 23(3):366-70. PubMed ID: 8508889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.